Sign up to save your podcasts
Or
Share Diet Drug Treats Both Forms of Diabetes
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Diet Drug Treats Both Forms of Diabetes
Vidcast: https://www.instagram.com/p/CxLvX4cR6Ap/
Semaglutide, the current “it” drug for weight loss, that was initially approved for management of non-insulin requiring diabetes, type 2 diabetes, cuts and even eliminates the need for insulin injections by type 1 diabetics. This small University of Buffalo study was just published in the New England Journal of Medicine.
Endocrinologists there studied 10 recently diagnosed diabetes type 1 patients. Each person was begun on injectable insulin both over the day and at mealtimes but was also given semaglutide. Over a 90 day period during which the semaglutide dose was increased, all were able to eliminate insulin for meals. Over 6 months, 7 of the 10 eliminated the need for any insulin. During the study, the mean HbA1c of the group fell from 11.7 to 5.7. Normal is less than 7
These incredible findings, if confirmed in a larger, randomized, double-blinded study, could revolutionize the management of so-called insulin-dependent diabetes. Stay tuned.
https://www.nejm.org/doi/10.1056/NEJMc2302677
#diabetes #semaglutide #insulin #HbA1c #ubuffalo #nejm
diabetes, semaglutide, insulin, HbA1c, ubuffalo, nejm
View all episodes
By Howard G. Smith MD, AMVidcast: https://www.instagram.com/p/CxLvX4cR6Ap/
Semaglutide, the current “it” drug for weight loss, that was initially approved for management of non-insulin requiring diabetes, type 2 diabetes, cuts and even eliminates the need for insulin injections by type 1 diabetics. This small University of Buffalo study was just published in the New England Journal of Medicine.
Endocrinologists there studied 10 recently diagnosed diabetes type 1 patients. Each person was begun on injectable insulin both over the day and at mealtimes but was also given semaglutide. Over a 90 day period during which the semaglutide dose was increased, all were able to eliminate insulin for meals. Over 6 months, 7 of the 10 eliminated the need for any insulin. During the study, the mean HbA1c of the group fell from 11.7 to 5.7. Normal is less than 7
These incredible findings, if confirmed in a larger, randomized, double-blinded study, could revolutionize the management of so-called insulin-dependent diabetes. Stay tuned.
https://www.nejm.org/doi/10.1056/NEJMc2302677
#diabetes #semaglutide #insulin #HbA1c #ubuffalo #nejm
diabetes, semaglutide, insulin, HbA1c, ubuffalo, nejm